In July 2026, the FDA approved a new medication for ADHD that works differently from anything currently on the market. Centanafadine, sold under the brand name Simtriyo, is the first and only approved medication that inhibits reuptake of all three key neurotransmitters implicated in attention and impulse control: norepinephrine, dopamine, and serotonin. For patients and families who have cycled through stimulants without success, or who cannot tolerate their side effects, this approval matters.
What Is Centanafadine?
Centanafadine (Simtriyo) is a once-daily, extended-release capsule approved for ADHD in adults and children aged 6 and older who weigh at least 20 kg. Unlike the amphetamine and methylphenidate-based stimulants that dominate ADHD treatment, centanafadine is classified as a triple reuptake inhibitor, meaning it blocks the reabsorption of norepinephrine, dopamine, and serotonin simultaneously, allowing each neurotransmitter to remain active in the synapse longer.
The approval was supported by four separate phase 3 clinical trials spanning both pediatric and adult populations. Manufacturer Otsuka expects the medication to become commercially available later this year.
RESEARCH SNAPSHOT
Centanafadine is the first FDA-approved triple reuptake inhibitor for ADHD. Most current ADHD medications fall into two categories: stimulants that primarily raise dopamine and norepinephrine, and non-stimulants like atomoxetine or viloxazine that act more narrowly on norepinephrine. A medication that engages serotonin as well introduces a novel mechanism that researchers are still characterizing in terms of long-term comparative efficacy.
A Familiar Story
Consider a composite patient, "Marcus," a 24-year-old graduate student. Marcus was diagnosed with ADHD in college after years of assuming his scattered focus and chronic procrastination were just personality traits. His first prescriber started him on a standard amphetamine salt combination. It helped his focus, but it also spiked his anxiety, suppressed his appetite to the point of noticeable weight loss, and left him wired and unable to sleep before exams. A switch to a methylphenidate formulation reduced the anxiety somewhat but introduced an uncomfortable afternoon crash as the medication wore off.
Patients like Marcus are exactly who a non-stimulant option with a novel mechanism is designed for: people whose ADHD symptoms are real and impairing, but whose nervous systems do not tolerate traditional stimulant pharmacology well. Because centanafadine is not a scheduled controlled substance in the way stimulants are, it also may appeal to patients concerned about dependence potential or who have a personal or family history of substance use.
How It Compares to Existing Options
Stimulant medications remain the most effective first-line treatment for ADHD by response rate, and that is unlikely to change based on this approval alone. But the ADHD medication landscape has been steadily diversifying over the past several years, with viloxazine (Qelbree), atomoxetine (Strattera), and now centanafadine offering mechanisms that do not touch the same reward pathways as stimulants.
What sets centanafadine apart from those existing non-stimulants is the addition of dopamine reuptake inhibition alongside norepinephrine and serotonin. Dopamine is central to the motivation and reward circuitry most disrupted in ADHD, and its relative absence from other non-stimulant options has often meant those medications, while safer for some patients, deliver a less robust effect on core inattentive symptoms. Whether centanafadine closes that gap in real-world practice, rather than just in trial data, is something clinicians will be watching closely over its first year on the market.
What This Means for Patients
If you or your young adult child have struggled to find an ADHD medication that works without unacceptable side effects, or if stimulant therapy has felt like the wrong fit for other reasons, centanafadine represents a genuinely new option rather than another reformulation of an existing drug class. As with any new medication, insurance coverage, long-term safety data, and individual response will take time to fully establish. A thorough psychiatric evaluation remains the best way to determine whether a novel mechanism like this one is right for your specific presentation.
Struggling to Find the Right ADHD Treatment?
Dr. Mark Agresti offers comprehensive, integrative ADHD evaluations for young adults, combining the latest pharmacological options with nutritional and lifestyle strategies. In-person appointments available in Palm Beach, with telemedicine offered statewide throughout Florida.
44 Cocoanut Row, Suite M202, Palm Beach, FL 33480
(561) 760-4107 | [email protected] | DrMarkAgresti.com
Keywords: centanafadine, Simtriyo, ADHD medication 2026, triple reuptake inhibitor, new ADHD drug, non-stimulant ADHD treatment, adult ADHD Palm Beach, ADHD psychiatrist Florida
Hashtags: #ADHD #Centanafadine #Simtriyo #ADHDTreatment #PsychiatryNews #FDAApproval #AdultADHD #PalmBeachPsychiatrist #MentalHealth #NonStimulant